Skip to main content
OpenTrials
Completed

NCT Number: NCT04139564

EaseVRx for the Reduction of Chronic Pain and Opioid Use

EaseVRx, a software-based virtual reality (VR) medical device, is intended to offer users a prescription pain management tool that manages the symptoms associated with chronic pain and reduces or eliminates the risk of opioid dependence. The investigators will conduct a proof-of-concept randomized study to assess the feasibility and efficacy of using EaseVRx as a 56-day, VR-based, at-home program among 100 chronic low back pain patients by gathering pilot data on the efficacy of the intervention in decreasing pain, reducing opioid/non-opioid pharmacotherapy, and improving pain-related quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Geisinger Medical Center

Danville, Pennsylvania, 17822, United States

About this study

EaseVRx, a software-based virtual reality (VR) medical device, is intended to offer users a prescription pain management tool that manages the symptoms associated with chronic pain and reduces or eliminates the risk of opioid dependence. EaseVRx is based on principles of cognitive behavioral therapy, pain psychology, mindfulness-based stress reduction, biofeedback, and distraction therapy commonly used in interdisciplinary pain rehabilitation programs. The investigators will conduct a proof-of-concept randomized study to assess the feasibility and efficacy of using EaseVRx as a 56-day, VR-based, at-home program among 100 chronic low back pain patients by gathering pilot data on the efficacy of the intervention in decreasing pain, reducing opioid/non-opioid pharmacotherapy, and improving pain-related quality of life. While VR has been tested in academic medical centers and shown to be efficacious in the management of acute pain, this study will investigate the feasibility of VR use at home to manage chronic pain in preparation for a larger efficacy trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years old
  • Low back pain experienced ≥ 3 days per week on average for ≥ 6 months
  • Pre-medication NPRS score ≥ 5 stable for ≥ 3 months

Exclusion criteria

  • Exclusions based on potential medical or lifestyle confounders:
  • Has a body mass index (BMI) > 40 kg/m2
  • Pain related to cancer, fibromyalgia, or disk herniation
  • History of a major psychiatric disorder not controlled with medication or has behavioral factors that would interfere with proper study procedures
  • Is not ambulatory/has significant motor impairment
  • Surgery in the past 3 months
  • Open workers compensation claim
  • Planning to have surgery in the next 3 months
  • Planning to start a new exercise program in the next 3 months
  • Planning to start a new treatment for their pain (e.g. medication, physiotherapy, acupuncture, electrical nerve stimulation) in the next 3 months
  • Exclusions based on potential drug-related cofounders:
  • Current or recent history (in past year) of substance abuse disorder
  • Currently pregnant/breastfeeding or planning to in the next 3 months
  • Was administered an epidural steroid during the 3 months prior to screening
  • Exclusions based on ability to use EaseVR effectively:
  • Comorbidities including neurological, psychosocial, sensory, or other disorders that may impact pain perception
  • Diagnosis of epilepsy, dementia, migraines, or other neurological disorders that may prevent VR usage, and/or other medical conditions predisposed to nausea and dizziness
  • Hypersensitivity to flashing lights or motion
  • Claustrophobia
  • Lack of stereoscopic vision
  • Severe hearing impairment
  • Injury to eyes, face, or neck that prevents comfortable VR usage
  • Planning to take a vacation from their home for more than one week in the next 8 weeks

Treatment and study plan

EaseVRx headset

Device

EaseVRx is a virtual reality therapy intended to treat chronic pain

Active control VR sham program

Device

VR, 2d visual wildlife scenes similar to some EaseVRx content

Primary outcomes

  1. Pain: Numerical Pain Rating Scale

    Time frame: 12 weeks

    Numerical Pain Rating Scale; scale from 0 to 10 with higher numbers implying greater pain

    The outcome values presented below are the difference between baseline pain and pain at 12 weeks. Specifically, baseline pain score minus 12 week pain score

    A positive difference implies that pain was reduced

Secondary outcomes

  1. Number of Outcome Assessments Completed by Participant

    Time frame: 12 weeks

    Thirty four assessments were attempted. This measure notes the total number of assessments completed by each participant

  2. Patient Compliance

    Time frame: 8 weeks

    number of VR modules completed. For the EaseVRx group this would be the number of EaseVRx modules completed with worst 0 - 56 best. For the Active control VR Sham group this would be the number of ShamVR modules completed with worst 0 - 56 best.

  3. Opioid Consumption

    Time frame: 12 weeks

    Morphine Milligram Equivalents (MME)

Sponsors and collaborators

Lead sponsor

AppliedVR Inc.

Industry

Collaborators

  • Geisinger Clinic
  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Safety and Effectiveness of Virtual Reality Utilizing EaseVRx for the Reduction of Chronic Pain and Opioid Use

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Oct 25, 2019
Registry last updated
Mar 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.